Hyperthermia Blog

News and Opinions About Our Industry

Pyrexar will be exhibiting at this year's ABS (American Brachytherapy Society) annual meeting in Miami, Florida. The conference held at the Intercontinental Miami hotel, June 13th through the 15th.

Pyrexar exhibits at the American Brachytherapy Society annual meeting miami florida

This is our first time exhibiting at the conference, and we believe we have a compelling solution to offer. HDR (high dose rate) brachytherapy and hyperthermia share some of the same market challenges. The bottom line is that brachytherapy plus hyperthermia improve cancer patient outcomes.

Like hyperthermia, brachytherapy is a sub-specialty that requires a specific skill set to treat patients. And like hyperthermia, brachytherapy is known to produce increased tumor control without an increase in toxicity. Product planning for hyperthermia is very similar, and the system utilizes the existing brachy catheters placed during HDR.

This month the 33rd Annual Meeting of the European Society for Hyperthermic Oncology (ESHO 2019) will be held in Warsaw, Poland, at the Warsaw Plaza Hotel, on May 22 - 24, 2019. The conference invites thermal oncology professionals with extensive clinical and scientific experience to share their expertise in the field.

ESHO 2019 Warsaw, PolandPyrexar Medical is represented by our European distribution partner Dr. Sennewald Medizintechnik and Poland distributor HT Systems.

Pyrexar Represented by:

Dr. Sennewald Medizintechnik Hyperthermia medical device company HT systems Hyperthermia medical device company

 The conference includes over 58 presentations by leading hyperthermia experts. Highlights below:

MR thermometry validation and modeling of a 915 MHz annular phased-array in brain phantoms Paul Turner
A meta-analysis of clinical trials with hyperthermia Niloy Datta
Protons and hyperthermia: early clinical results Zeljko Vujaskovic
Building an international forum to boost hyperthermic research Stephan Bodis
Quality assurance guidelines for hyperthermia H. Dobsicek Trefna
Quality assurance assessment: are commercial MR-guided deep-pelvic hyperthermia devices ready for a large clinical trial? Sergio Curto
QA techniques for radiative deep hyperthermia systems: benefits and limitations of 1D, 2D, and 3D techniques Gerard van Rhoon
Combined interstitial radiotherapy with interstitial hyperthermia Andrzej Kukielka
Thermochemoradiotherapy for locally advanced pancreatic cancers: A pilot study Niloy Datta
Radiotherapy in combination with regional Hyperthermia for Salvage Treatment in refractory Childhood Cancer Rudiger Wessalowski
Full program available here.

A special thanks to the 2019 ESHO committee for organizing this year's event and to the Maria Sklodowska-Curie Institute — Oncology Center for hosting the hyperthermia workshops.

estro38 Dr. Sennewald Medizintechnik, Pyrexar's European distribution partner,  has brought together an impressive program of clinicians to talk about hyperthermia's role in the treatment of cancer, at this years ESTRO 38 (European Society for Radiotherapy & Oncology).  The luncheon symposium titled "Hyperthermia in the age of personalized oncology" will be held Saturday, April 27th, and is open to all ESTRO attendees (space is limited).

Program outline below:

Introduction Daniel Zips, UMC Tübingen, Germany
Hyperthermia as an immune modulator in multimodal tumor therapies - immune biological rationale Michael Hader, Ph.D., UMC Erlangen, Germany
Integration of Pencil Beam Scanning Proton Therapy and Hyperthermia: The University of Maryland Clinical Experience Zeljko Vujaskovic MD, University of Maryland, USA
Management of locally recurrent Breast Cancers with local hyperthermia and radiotherapy: A systematic review and meta-analysis Niloy Datta MD, Canton Hospital Aarau, Switzerland
Neoadjuvant chemotherapy combined with deep regional hyperthermia as the new standard for the treatment of patients with high-risk soft-tissue sarcomas Lars Lindner MD,  UMC Munich Grosshadern, Germany
Hyperthermia and preoperative chemoradiation for organ-preservation in rectal cancer patients Cihan Gani MD, UMC Tübingen, Germany
Discussion and Summary Stephan Bodis MD, Canton Hospital Aarau, Switzerland

ABOUT ESTRO

Founded in 1980, ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organization that fosters the role of Radiation Oncology to improve patients’ care in the multimodality treatment of cancer. ESTRO 38 is held in Milan, Italy, April 26th - 30th, 2019, at the Milan Convention Center.

Pyrexar Celebrates four years as a medical device manufacturer

It has been four years since we acquired the hyperthermia division from BSD Medical and started Pyrexar Medical.  In addition to getting the technology rights to this life-changing technology, we also received a group of great, hardworking people. Pyrexar may be only celebrating year four, but we do this sitting atop four decades of drive, innovation, and the desire to give those that are battling cancer, a higher chance at disease-free survival.

We are looking toward achieving great strides in this next year. With that, we have many people to thank, and that includes you.  Thank you to all of our supporters, partners, researchers, physicians, physicists, radiation therapists, nurses, and administrative staff around the world. To those that continue to believe in the bright future of hyperthermia and to those who demand the best outcomes for their patients.

Thank you.